-+ 0.00%
-+ 0.00%
-+ 0.00%

Polyrizon completes US clinical site network for NASARIX seasonal allergic rhinitis trial

PUBT·08/20/2026 13:30:20
Listen to the news
Polyrizon completes US clinical site network for NASARIX seasonal allergic rhinitis trial
  • Polyrizon completed contracting for all five U.S. sites for its first-in-human NASARIX Allergy Blocker study in seasonal allergic rhinitis.
  • Results have not been presented; the trial is moving into pre-screening, with enrollment timed to allergy seasons under real-world pollen exposure.
  • The study aims to show NASARIX can reduce allergy symptoms versus a saline spray, while remaining safe and well tolerated.
  • Up to 120 patients are expected to be randomized, supporting the company’s plan to advance the product toward the U.S. market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200930PRIMZONEFULLFEED9813449) on August 20, 2026, and is solely responsible for the information contained therein.